ULTRAGENYX PHARMACEUTICAL INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Product Sales Net | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Collaboration and License Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Royalty Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $1.0K | — | — | — | — | — | — | — |
| Gross Profit | $-1.0K | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $231.6M | $183.2M | $114.7M | $46.0M | $27.8M | $12.6M | — | — |
| SG&A Expense | $99.9M | $64.9M | $33.0M | $10.8M | $4.5M | $3.3M | — | — |
| Operating Income | $-328.9M | $-248.0M | $-147.7M | $-56.8M | $-32.3M | $-16.0M | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-318.3M | $-245.8M | $-145.6M | $-59.8M | — | — | — | — |
| Income Tax Expense | $-16.2M | $35.0K | $0 | $0 | $0 | — | — | — |
| Net Income | $-302.1M | $-245.9M | $-145.6M | $-59.8M | $-35.1M | $-16.3M | — | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-7.12 | $-6.21 | $-3.96 | $-2.25 | $-1.86 | $-1.78 | — | — |
| EPS (Diluted) | $-7.12 | $-6.21 | $-3.96 | $-2.25 | $-1.86 | $-1.78 | — | — |
| Shares Outstanding (Basic) | 44.2M | 41.2M | 36.8M | 28.8M | 28.7M | 25.0M | — | — |
| Shares Outstanding (Diluted) | 44.2M | 41.2M | 36.8M | 28.8M | 28.7M | 25.0M | — | — |
| Dividends Per Share | — | — | $0.00 | $0.00 | — | — | — | — |